Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (14562)	2/11/1998 12:18:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

I believe that Taxol was recently approved for KS also. See Panretin oral treatment of KS section of home.att.net New therapies shrink lesions, reduce pain and other symptoms The past few months have brought encouraging news about several treatments for Kaposi's sarcoma (KS), both approved and experimental. First, the F.D.A. approved Bristol-Myers Squibb's anti-cancer drug Taxolr for use against KS. Clinical studies have demonstrated that Taxol, while it does not cure KS, shrinks the lesions associated with this skin cancer and reduces the pain caused by the lesions. Researchers report that Taxol has proven effective in reducing lesion size in some people with KS who have failed to respond to other therapies. Next, doctors from the University of California at San Francisco reported that five patients with KS experienced improvement when they began taking the protease inhibitor ritonavir (Norvirr). In all five cases ritonavir was added to whatever combination of antiviral drugs the patients were already taking. It is impossible to say, at this point, if the response that was seen in this handful of patients was a specific to ritonavir or was yet another demonstration of the potency of the protease inhibitors as a class. It remains to be seen if ritonavir alone will prove to be a useful weapon against KS. Finally, Allergan Ligand Retinoid Therapeutics reported promising results for its experimental KS therapy, panretin topical gel, and applied for F.D.A. approval. Allergan Ligand is also testing an oral version of panretin.